Cantitate/Preț
Produs
Total produse
Vezi coșul
Safety Evaluation of Pharmaceuticals and Medical Devices: International Regulatory Guidelines de Shayne C. Gad

Safety Evaluation of Pharmaceuticals and Medical Devices: International Regulatory Guidelines

Autor Shayne C. Gad
en Limba Engleză Paperback – 7 oct 2014
The inspiration for this text was the 1988 volume by Alder and Zbinden, written before the ICH harmonization process for drug safety evaluation (or its ISO analog for device biocompatibility evaluation) had been initiated or come to force. Since then, much has changed in both the world and practice of medicine and the regulation of drugs. The intent of this volume is to provide similar guidance as to what nonclinical safety assessment tests need to be performed to move a drug into man, through development and to market approved (this intent was subsequently extended to cover the closely related medical device biotechnology, and combination product fields) in a concise, abbreviated manner for all the major world market countries.
Citește tot Restrânge

Toate formatele și edițiile

Toate formatele și edițiile Preț Express
Paperback (1) 106365 lei  6-8 săpt.
  Springer Us – 7 oct 2014 106365 lei  6-8 săpt.
Hardback (1) 106619 lei  6-8 săpt.
  Springer Us – 26 oct 2010 106619 lei  6-8 săpt.

Preț: 106365 lei

Preț vechi: 111964 lei
-5% Nou

Puncte Express: 1595
Preț estimativ în valută:
20359€ • 21348$ • 16822£

Carte tipărită la comandă

Livrare economică 29 ianuarie-12 februarie 25

 Adaugă în coș

Wish list
Gift list
Am citit!
Adaugă în listă
Preluare comenzi: 021 569.72.76

Specificații

ISBN-13: 9781489981875
ISBN-10: 148998187X
Pagini: 140
Ilustrații: XI, 126 p.
Dimensiuni: 155 x 235 x 7 mm
Greutate: 0.2 kg
Ediția:2011
Editura: Springer Us
Colecția Springer
Locul publicării:New York, NY, United States

Public țintă

Research

Cuprins

Preface1. Introduction to Safety Assessment in Drug and Medical Device Development2. Drugs: The General Case3. Ind Enabling Toxicology Programs4. Nonclinical Safety Evaluation Studies Conducted To Support Continued Clinical Development5. Supporting Marketing Applications6. Special Therapeutic Category And Route Of Administration Cases7. Device Safety EvaluationAppendix AINDEX

Notă biografică

Shayne C. Gad, B.S. (Whittier College, Chemistry and Biology, 1970) and Ph.D. in Pharmacology/Toxicology (Texas, 1977) DABT, ATS, is the principal of Gad Consulting Services, a seventeen year old consulting firm with six employees and more than 450 clients (including 120 pharmaceutical companies in the US and 50 overseas). Prior to this, he served in director-level and above positions at Searle, Synergen and Becton Dickinson. He has published 39 books and more than 350 chapters, articles and abstracts in the fields of toxicology, statistics, pharmacology, drug development and safety assessment. He has more than 33 years of broad based experience in toxicology, drug and device development, statistics and risk assessment. He has specific expertise in neurotoxicology, in vitro methods, cardiovascular toxicology, inhalation toxicology, immunotoxicology, and genotoxicology. Past President of the American College of Toxicology, the Roundtable of Toxicology Consultants and three of SOT’s specialty sections, and recipient of the American College of Toxicology Lifetime Contribution Award. He has direct involvement in the preparation of INDs (90 successfully to date), NDA, PLA, ANDA, 510(k), IDE, CTD, clinical data bases for phase 1 and 2 studies, and PMAs. He has consulted for FDA, EPA and NIH, and has trained reviewers and been an expert witness for FDA. He has also conducted the triennial toxicology salary survey as a service to the profession for the last 19 years.

Textul de pe ultima copertă

Safety Evaluation of Pharmaceuticals and Medical Devices has been written to provide complete, ready and clear guidance as to what nonclinical safety assessment tests need to be performed to move a regulated therapeutic medical product into and through the development process and to marketing approval. This intent is purposely extended to cover the closely related product types of vaccines, biotechnology products, gene therapy, cell therapy, and combination products into a single, concise guide for the process in all the major world market countries.
The approach of this volume is to first address the broadest scope “general case” for the regulatory nonclinical safety evaluation by ICH and ISO adhering countries, then to branch out to cover the differences in requirements associated with specific therapeutic areas (such as oncology), major routes of administration (with oral being the general case, other routes starting with parentheral, dermal and inhalation are addressed). Large molecules biotechnology products are then considered, followed by special courses of product marketing approval, and finally the remaining national differences.

Caracteristici

Nonclinical safety assessment tests
Large molecules biotechnology products
National differences
Includes supplementary material: sn.pub/extras